论文部分内容阅读
目的探讨中药结合干扰素联合化疗治疗晚期非小细胞肺癌对患者血清血管内皮细胞生长因子(VEGF)、CA153及人细胞角蛋白21-1(CYFRA21-1)水平的影响。方法将200例晚期非小细胞肺癌患者随机分为中药结合干扰素联合化疗治疗的研究组(100例)和干扰素联合化疗治疗的对照组(100例)。分别在2组治疗前后检测血清VEGF、CA153及CYFRA21-1水平。结果治疗前2组血清VEGF、CA153及CYFRA21-1水平差异无统计学意义(P>0.05);经过治疗后2组血清VEGF、CA153及CYFRA21-1水平较治疗前均显著性的降低(P<0.05),且研究组低于对照组,差异有统计学意义(P<0.05)。结论采用中药结合干扰素联合化疗对晚期非小细胞肺癌进行治疗,能有效的降低患者体内血清VEGF、CA153及CYFRA21-1水平。
Objective To investigate the effect of traditional Chinese medicine combined with interferon plus chemotherapy on serum levels of vascular endothelial growth factor (VEGF), CA153 and human cytokeratin 21-1 (CYFRA21-1) in patients with advanced non-small cell lung cancer. Methods 200 patients with advanced non-small cell lung cancer were randomly divided into the study group (100 cases) treated with combination of interferon and chemotherapy and the control group (100 cases) treated with interferon and chemotherapy. Serum levels of VEGF, CA153 and CYFRA21-1 were measured before and after treatment in both groups. Results There was no significant difference in the serum levels of VEGF, CA153 and CYFRA21-1 between the two groups before treatment (P> 0.05). After treatment, the serum levels of VEGF, CA153 and CYFRA21-1 in the two groups were significantly lower than those before treatment (P < 0.05), and the study group was lower than the control group, the difference was statistically significant (P <0.05). Conclusions The treatment of advanced non-small cell lung cancer with traditional Chinese medicine and interferon combined with chemotherapy can effectively reduce the levels of serum VEGF, CA153 and CYFRA21-1 in patients.